Madrigal Pharmaceuticals (MDGL) Common Equity (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Common Equity of $523.7 million for Q2 2026, down 24.75% year-over-year from $696.0 million in Q2 2025, and down 3.63% quarter-over-quarter from $543.5 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Common Equity (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Common Equity for 17 consecutive years, with $523.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity fell 24.75% year-over-year to $523.7 million; the TTM figure through Jun 2026 stood at $523.7 million (down 24.75% YoY), while the FY2025 annual figure was $602.7 million, down 20.11% from the prior year.
- Common Equity eased to $523.7 million in Q2 2026 per MDGL's latest filing, from $543.5 million in the prior quarter.
- Across five years, Common Equity topped out at $857.1 million in Q2 2024 and bottomed at $10.7 million in Q3 2022.
- Historically, Common Equity has averaged $447.8 million across 5 years, with a median of $533.6 million in 2026.
- Annual changes were most pronounced in 2022 — Common Equity plunged 95.46% — and 2024, when it surged 3392.99%.
- Madrigal Pharmaceuticals' Common Equity stood at $197.4 million in 2022, then surged by 105.35% to $405.3 million in 2023, then surged by 86.11% to $754.4 million in 2024, then retreated by 20.11% to $602.7 million in 2025, then declined by 13.1% to $523.7 million in 2026.
- Business Quant data shows MDGL's Common Equity at $523.7 million in Q2 2026, $543.5 million in Q1 2026, and $602.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 523.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 523.72 Mn |
| Mar 31, 2026 | 543.45 Mn |
| Dec 31, 2025 | 602.69 Mn |
| Sep 30, 2025 | 625.73 Mn |
| Jun 30, 2025 | 695.98 Mn |
| Mar 31, 2025 | 710.64 Mn |
| Dec 31, 2024 | 754.38 Mn |
| Sep 30, 2024 | 777.16 Mn |
| Jun 30, 2024 | 857.12 Mn |
| Mar 31, 2024 | 850.76 Mn |
| Dec 31, 2023 | 405.33 Mn |
| Sep 30, 2023 | 22.25 Mn |
| Jun 30, 2023 | 103.51 Mn |
| Mar 31, 2023 | 150.14 Mn |
| Dec 31, 2022 | 197.39 Mn |
| Sep 30, 2022 | 10.67 Mn |
| Jun 30, 2022 | 83.54 Mn |
| Mar 31, 2022 | 145.74 Mn |
| Dec 31, 2021 | 196.11 Mn |
| Sep 30, 2021 | 234.88 Mn |